Complete Wegovy vs Mounjaro Dosing Breakdown
Understanding Wegovy 1.7mg Equivalent to Mounjaro Starter Protocols
When comparing Wegovy 1.7mg equivalent to Mounjaro dosing, the key difference lies in their escalation timelines and mechanisms. Wegovy (semaglutide) follows a structured 16-week dose escalation, reaching 1.7mg at weeks 13-16 before the final 2.4mg maintenance dose. Mounjaro (tirzepatide) uses a different schedule entirely, starting at 2.5mg and escalating every 4 weeks to 5mg, 7.5mg, 10mg, and potentially 15mg maximum.
The starter phase for both treatments requires careful consideration of your medical history and tolerance levels. Wegovy's gentle 0.25mg starting dose allows your body to adjust to GLP-1 receptor stimulation gradually, whilst Mounjaro's dual GIP and GLP-1 mechanism begins at a higher equivalent dose. Neither approach is inherently superior—the choice depends on your prescriber's clinical judgement and your individual response to treatment alongside a reduced-calorie diet and increased physical activity.
Pricing Comparison: Wegovy 1.7mg Equivalent to Mounjaro Costs
Wegovy 1.7mg costs £139.99 per pen, representing weeks 13-16 of your treatment journey after completing the lower starter doses. New customers benefit from code FIRST40 at checkout, whilst returning customers use DOSE25 for continued savings. The complete Wegovy starter pathway begins with 0.25mg at £79.99, progressing through 0.5mg (£94.99) and 1mg (£99.99) before reaching the 1.7mg dose.
For convenience, our Intro Trio bundle (0.25mg, 0.5mg, and 1mg) provides your first 12 weeks for £299.99, transitioning seamlessly to the 1.7mg dose. Mounjaro pricing follows a different structure, reflecting its unique dosing requirements. Both treatments are available through EverydayMeds with identical clinical assessment standards and next-day delivery—your prescriber can help determine which represents better value for your specific treatment goals.
Clinical Evidence: Wegovy 1.7mg Equivalent to Mounjaro Efficacy
The STEP trials demonstrated that patients taking Wegovy alongside lifestyle modifications achieved significant weight management outcomes, with the 1.7mg dose representing a crucial stepping stone towards maintenance therapy. Wilding et al., NEJM, 2021, showed consistent efficacy across the dose escalation range. The 1.7mg dose may help bridge the gap between intermediate dosing and full therapeutic effect.
Mounjaro's clinical profile stems from separate SURMOUNT trials, making direct comparison challenging due to different study populations and endpoints. Both treatments work through appetite regulation mechanisms, though Mounjaro's dual GIP and GLP-1 action differs from Wegovy's selective GLP-1 approach. Individual response varies significantly, making personalised medical assessment essential for determining which treatment pathway suits your circumstances best.
How Wegovy 1.7mg Works in Your Weight Management Journey
Wegovy operates as a GLP-1 receptor agonist, mimicking the natural incretin hormones that regulate appetite and food intake after meals. At the 1.7mg dose level, you're approaching near-maximum receptor activation, which may result in enhanced appetite suppression and improved satiety signals. The medication works primarily through brain appetite centres, particularly the hypothalamus, where it can influence food cravings and portion control. This physiological action supports your dietary changes rather than replacing the need for lifestyle modifications. The 1.7mg phase often represents when many patients notice stabilising side effects whilst maintaining therapeutic benefits, making it a crucial transition period in treatment.
Streamlined Ordering Process for Wegovy 1.7mg Equivalent to Mounjaro
Beginning your Wegovy journey requires just a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our GPhC-registered prescribers (#9012878) review applications within 3 working days (24-hour express service available), ensuring thorough evaluation before approving this prescription-only medicine. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain logistics to maintain efficacy. All orders include comprehensive patient information leaflets and injection guidance specific to your prescribed dose. Whether starting at 0.25mg or transitioning to 1.7mg, our clinical team provides ongoing support throughout your treatment progression.
Storage and Practical Considerations for Wegovy 1.7mg
Wegovy requires refrigerated storage at 2-8°C before first use, offering a significant practical advantage with 6 weeks room temperature stability once removed from the fridge (compared to Mounjaro's 21-day limit). The FlexTouch pen design ensures accurate 1.7mg dosing with each weekly injection, typically administered on the same day each week. This dose represents weeks 13-16 of treatment, meaning you cannot skip directly to 1.7mg from lower doses due to safety protocols. Proper dose escalation remains mandatory for minimising side effects and ensuring therapeutic effectiveness. The 1.7mg strength uses a distinctive pen colour coding system to prevent dosing errors during your treatment journey.
Why the 1.7mg Dose Represents a Critical Treatment Milestone
The Wegovy 1.7mg equivalent to Mounjaro comparison becomes most relevant at this specific dose level because you're approaching maintenance therapy decisions. At weeks 13-16, most patients have experienced their body's adaptation to GLP-1 stimulation and can evaluate treatment effectiveness more accurately. This timing often coincides with considering long-term treatment sustainability and cost optimisation strategies.
Many patients find the 1.7mg phase ideal for assessing whether the final step to 2.4mg maintenance is necessary, or whether this dose provides sufficient appetite control for their goals. Unlike starting doses where side effect management takes priority, the 1.7mg level allows focus on fine-tuning your weight management approach and planning your ongoing treatment pathway with confidence.
Making Your Treatment Decision: Wegovy or Mounjaro
Both Wegovy and Mounjaro represent clinically proven approaches to weight management, each with distinct advantages depending on your medical profile and treatment preferences. Wegovy's established dose escalation pathway provides predictable progression, whilst Mounjaro's dual mechanism may suit patients seeking alternative therapeutic approaches. Cost considerations, injection frequency, and storage requirements all factor into your decision-making process alongside clinical effectiveness. The 1.7mg Wegovy dose costs £139.99, with discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied at checkout for additional value. Both treatments are available from EverydayMeds following thorough clinical assessment, ensuring you receive appropriate medical oversight regardless of your choice. Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
